In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

HIV-1 envelope glycoprotein [Env; trimeric (gp160) 3 cleaved to (gp120/gp41) 3] attaches
the virion to a susceptible cell and induces fusion of viral and cell membranes to initiate …

HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …

Vaccines generate high-affinity antibodies by recruiting antigen-specific B cells to germinal
centers (GCs), but the mechanisms governing the recruitment to GCs on secondary …

The upper airway is an important site of infection, but immune memory in the human upper
airway is poorly understood, with implications for COVID-19 and many other human …

HIV-1 vaccine development has been stymied by an inability to induce broadly reactive
neutralizing antibodies to the envelope (Env) trimer, the sole viral antigen on the virion …

Antibodies serve as critical barriers to viral infection. Humoral immunity to a virus is achieved
through the dual role of antibodies in communicating the presence of invading pathogens in …

Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

HIV-1 Env mediates viral entry into host cells and is the sole target for neutralizing
antibodies. However, Env structure and organization in its native virion context has eluded …

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …